GlassScriptPhysician profile
Kanwar T Mahal
NPI 1154455806
$7,712.84
in general payments reported to CMS, 2019-2025
52 companies · $1,158 in 2025
The $1,158 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,901 · 2020: $506 · 2021: $830 · 2022: $923 · 2023: $1,231 · 2024: $1,163 · 2025: $1,158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,552.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,415.47 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $739.98 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $619.52 | 2019-2024 | Otezla, Repatha |
| Lilly USA, LLC | $570.92 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $460.23 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $428.98 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $346.13 | 2019-2025 | Rexulti |
| Abbott Laboratories | $314.56 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $249.74 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Biotronik INC. | $168.01 | 2019 | |
| Amarin Pharma, INC. | $167.31 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.41 | 2019-2023 | Tradjenta, Jardiance, Synjardy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $137.53 | 2019-2024 | Xifaxan |
| Astellas Pharma US INC | $136.03 | 2023-2025 | Veozah, Vesicare |
| Novartis Pharmaceuticals Corporation | $130.75 | 2019-2023 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kanwar Mahal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.